Market Trends Verstem avutometinib and defactinib combo gains FDA priority reviewBy admin8996erT0allJanuary 23, 2025 Professor25 The U.S. FDA has granted priority review to Verastem Oncology’s (NASDAQ:VSTM) combination of avutometinib and defactinib for a type…
